Last reviewed · How we verify
Intravenous lignocaine
Intravenous lignocaine, marketed by the Jawaharlal Institute of Postgraduate Medical Education & Research, holds a position in the anesthetic market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Intravenous lignocaine |
|---|---|
| Also known as | Lidocaine, Xylocard, IV lignocaine |
| Sponsor | Jawaharlal Institute of Postgraduate Medical Education & Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Sphenopalatine Ganglion Block for Post-Dural Puncture Headache: A Pilot Randomised Controlled Trial (NA)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
- Intravenous Lidocaine Infusion in Lumbar Fusion Surgery (NA)
- Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (PHASE4)
- Effect of IV Lidocaine on Duodenal Peristalsis and Sedation in ERCP (PHASE4)
- Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) (PHASE2)
- Application of Low-dose Muscle Relaxants in Bronchoscopic Interventional Procedures (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: